Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
TGFβR-SMAD3 Signaling Induces Resistance to PARP Inhibitors in the Bone Marrow Microenvironment.
Le BV, Podszywalow-Bartnicka P, Maifrede S, Sullivan-Reed K, Nieborowska-Skorska M, Golovine K, Yao JC, Nejati R, Cai KQ, Caruso LB, Swatler J, Dabrowski M, Lian Z, Valent P, Paietta EM, Levine RL, Fernandez HF, Tallman MS, Litzow MR, Huang J, Challen GA, Link D, Tempera I, Wasik MA, Piwocka K, Skorski T. Le BV, et al. Among authors: maifrede s. Cell Rep. 2020 Oct 6;33(1):108221. doi: 10.1016/j.celrep.2020.108221. Cell Rep. 2020. PMID: 33027668 Free PMC article.
IGH/MYC Translocation Associates with BRCA2 Deficiency and Synthetic Lethality to PARP1 Inhibitors.
Maifrede S, Martin K, Podszywalow-Bartnicka P, Sullivan-Reed K, Langer SK, Nejati R, Dasgupta Y, Hulse M, Gritsyuk D, Nieborowska-Skorska M, Lupey-Green LN, Zhao H, Piwocka K, Wasik MA, Tempera I, Skorski T. Maifrede S, et al. Mol Cancer Res. 2017 Aug;15(8):967-972. doi: 10.1158/1541-7786.MCR-16-0468. Epub 2017 Jun 20. Mol Cancer Res. 2017. PMID: 28634224 Free PMC article.
TET2 and DNMT3A Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors.
Maifrede S, Le BV, Nieborowska-Skorska M, Golovine K, Sullivan-Reed K, Dunuwille WMB, Nacson J, Hulse M, Keith K, Madzo J, Caruso LB, Gazze Z, Lian Z, Padella A, Chitrala KN, Bartholdy BA, Matlawska-Wasowska K, Di Marcantonio D, Simonetti G, Greiner G, Sykes SM, Valent P, Paietta EM, Tallman MS, Fernandez HF, Litzow MR, Minden MD, Huang J, Martinelli G, Vassiliou GS, Tempera I, Piwocka K, Johnson N, Challen GA, Skorski T. Maifrede S, et al. Cancer Res. 2021 Oct 1;81(19):5089-5101. doi: 10.1158/0008-5472.CAN-20-3761. Epub 2021 Jul 2. Cancer Res. 2021. PMID: 34215619 Free PMC article.
Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells.
Nieborowska-Skorska M, Sullivan K, Dasgupta Y, Podszywalow-Bartnicka P, Hoser G, Maifrede S, Martinez E, Di Marcantonio D, Bolton-Gillespie E, Cramer-Morales K, Lee J, Li M, Slupianek A, Gritsyuk D, Cerny-Reiterer S, Seferynska I, Stoklosa T, Bullinger L, Zhao H, Gorbunova V, Piwocka K, Valent P, Civin CI, Muschen M, Dick JE, Wang JC, Bhatia S, Bhatia R, Eppert K, Minden MD, Sykes SM, Skorski T. Nieborowska-Skorska M, et al. Among authors: maifrede s. J Clin Invest. 2017 Jun 1;127(6):2392-2406. doi: 10.1172/JCI90825. Epub 2017 May 8. J Clin Invest. 2017. PMID: 28481221 Free PMC article.
Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms.
Nieborowska-Skorska M, Maifrede S, Dasgupta Y, Sullivan K, Flis S, Le BV, Solecka M, Belyaeva EA, Kubovcakova L, Nawrocki M, Kirschner M, Zhao H, Prchal JT, Piwocka K, Moliterno AR, Wasik M, Koschmieder S, Green TR, Skoda RC, Skorski T. Nieborowska-Skorska M, et al. Among authors: maifrede s. Blood. 2017 Dec 28;130(26):2848-2859. doi: 10.1182/blood-2017-05-784942. Epub 2017 Oct 17. Blood. 2017. PMID: 29042365 Free PMC article.
MLL-AF9 leukemias are sensitive to PARP1 inhibitors combined with cytotoxic drugs.
Maifrede S, Martinez E, Nieborowska-Skorska M, Di Marcantonio D, Hulse M, Le BV, Zhao H, Piwocka K, Tempera I, Sykes SM, Skorski T. Maifrede S, et al. Blood Adv. 2017 Aug 9;1(19):1467-1472. doi: 10.1182/bloodadvances.2017006247. eCollection 2017 Aug 22. Blood Adv. 2017. PMID: 29296788 Free PMC article.
Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors.
Maifrede S, Nieborowska-Skorska M, Sullivan-Reed K, Dasgupta Y, Podszywalow-Bartnicka P, Le BV, Solecka M, Lian Z, Belyaeva EA, Nersesyan A, Machnicki MM, Toma M, Chatain N, Rydzanicz M, Zhao H, Jelinek J, Piwocka K, Sliwinski T, Stoklosa T, Ploski R, Fischer T, Sykes SM, Koschmieder S, Bullinger L, Valent P, Wasik MA, Huang J, Skorski T. Maifrede S, et al. Blood. 2018 Jul 5;132(1):67-77. doi: 10.1182/blood-2018-02-834895. Epub 2018 May 21. Blood. 2018. PMID: 29784639 Free PMC article.
Non-NAD-like PARP1 inhibitor enhanced synthetic lethal effect of NAD-like PARP inhibitors against BRCA1-deficient leukemia.
Nieborowska-Skorska M, Maifrede S, Ye M, Toma M, Hewlett E, Gordon J, Le BV, Sliwinski T, Zhao H, Piwocka K, Valent P, Tulin AV, Childers W, Skorski T. Nieborowska-Skorska M, et al. Among authors: maifrede s. Leuk Lymphoma. 2019 Apr;60(4):1098-1101. doi: 10.1080/10428194.2018.1520988. Epub 2018 Oct 2. Leuk Lymphoma. 2019. PMID: 30277116 Free PMC article. No abstract available.
Gadd45a deficiency accelerates BCR-ABL driven chronic myelogenous leukemia.
Mukherjee K, Sha X, Magimaidas A, Maifrede S, Skorski T, Bhatia R, Hoffman B, Liebermann DA. Mukherjee K, et al. Among authors: maifrede s. Oncotarget. 2017 Feb 14;8(7):10809-10821. doi: 10.18632/oncotarget.14580. Oncotarget. 2017. PMID: 28086219 Free PMC article.
20 results